echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > INOVIO announces the administration of the first subject of Lassa fever vaccine

    INOVIO announces the administration of the first subject of Lassa fever vaccine

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    INOVIO announced today that the Phase 1B clinical trial of INO-4500 (its Lassa fever DNA vaccine candidate) in Ghana has completed the first subject administration.


    About INOVIO's INO-4500 Phase 1B clinical trial

    INOVIO's Phase 1B clinical trial LSV-002 will recruit approximately 220 adult participants aged 18-50.


    Since its establishment in 1979, the Noguchi Memorial Medical Research Institute (hereinafter referred to as the "Institute") has carried out capacity building for the prevention and control of endemic diseases and emerging and recurring diseases in Ghana and West Africa, and has become a globally recognized leading biomedicine in Africa.


    About Lassa fever

    Lassa fever is an animal-borne acute hemorrhagic viral disease, mainly seen in parts of West Africa.


    The diagnosis of Lassa fever is difficult, there is a lack of standardized monitoring and testing, and many parts of West Africa where the outbreak occurs are usually remote, so the number of reported cases and deaths is likely to be much lower than the actual number of cases and deaths.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.